Immunosuppressive drug

Kalytera Therapeutics Acquires Israeli Cannabis Drugmaker

By JNi.Media

'The results of Talent’s Phase 2 clinical studies are unprecedented, and mark a major milestone in the potential prevention and treatment of this severe and life-threatening disease.'